General Information
Official company information
- Business Registration (BR) Number
- 73101900
- Company Registration Number
- F0029523
- Company Age
- 3 years
- Registration Date
-
- Registered Address
-
40/F DAH SING FINANCIAL CTR, NO 248 QUEEN'S RD EAST WANCHAI, HONG KONG
- Date of Name Change
- 19 July 2021
-
N/A
About Abbisko Cayman Limited
Company profile and description
Abbisko Cayman Limited is an investment holding company focusing on the research and development of pharmaceutical products. Founded in 2016, the company is headquartered in Shanghai, China, and develops various drug candidates for the treatment of different cancers and other diseases, including Pimicotinib, Irpagratinib, ABSK043, ABSK061, Fexagratinib, ABSK121, ABSK112, Mavorixafor, ABSK051, ABSK012, ABK131, ABK3376, and ABSK141. Abbisko Therapeutics Co., Ltd. is a subsidiary of Abbisko Cayman Limited (HKEX: 2256.HK). The company has secured $85 million as Merck exercises Pimicotinib option.
Category
Business category and classification details
- Primary Category
- Health & Medical
- Description
- Providers of medical, dental, therapeutic, and other health-related services, including hospitals, clinics, private practices, and pharmacies.
Additional Information
Detailed company information and status
- Company Type
- Registered non-Hong Kong company
- Location Code
- HK
- Company Origin
- Foreign Company
- Registration Status
- Active
Company Contacts
Key contacts and leadership
| Name & Position | Contact Number | Fax Number | |
|---|---|---|---|
Request For Information FreeWe will attempt to gather this information through our sources Current requests: 0 |
|||
Similar Companies
Companies in the same industry or category
-
Health & Medical -
Health & Medical -
YIHealth & Medical
-
BRHealth & Medical
In the News
Recent media coverage and press mentions
No recent media coverage
No recent news articles found for Abbisko Cayman Limited
